Payer and Specialty Pharmacy Forum: Clinical Updates and Outcomes Data for PCSK9 Inhibitors

https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-payer-and-specialty-pharmacy-forum-clinical-updates-and-outcomes-data-for-pcsk9-inhibitors

Related Videos

Related Content

Advertisement

July 26th 2025

How to Utilize a Multimodal Treatment Approach for Childhood Obesity

Pearl Steinzor

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 25th 2025

AllergyAware E-Learning Training Program Boosts Anaphylaxis Preparedness in School Staff

Cameron Santoro

The AllergyAware e-learning course effectively trained school personnel on anaphylaxis management, significantly improving their knowledge and confidence in using epinephrine auto-injectors, despite some technical and pacing issues reported by users.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

July 25th 2025

Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD

Pearl Steinzor

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).

Related Content

Advertisement

July 26th 2025

How to Utilize a Multimodal Treatment Approach for Childhood Obesity

Pearl Steinzor

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 25th 2025

AllergyAware E-Learning Training Program Boosts Anaphylaxis Preparedness in School Staff

Cameron Santoro

The AllergyAware e-learning course effectively trained school personnel on anaphylaxis management, significantly improving their knowledge and confidence in using epinephrine auto-injectors, despite some technical and pacing issues reported by users.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

July 25th 2025

Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD

Pearl Steinzor

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).